Washington State

House of Representatives

Office of Program Research

BILL

ANALYSIS

Health Care & Wellness Committee

HB 2325

This analysis was prepared by non-partisan legislative staff for the use of legislative members in their deliberations. This analysis is not a part of the legislation nor does it constitute a statement of legislative intent.

Brief Description: Concerning the prescription drug monitoring program.

Sponsors: Representatives Riccelli, Haler, Ryu, Pellicciotti, Harris, Macri, Tharinger, Valdez, Frame, Jinkins, Doglio, Pollet, Stonier, Appleton and Gregerson; by request of Attorney General.

Brief Summary of Bill

  • Requires practitioners prescribing an opiate or benzodiazepine to review the patient's controlled substance history in the prescription monitoring program.

  • Exempts practitioners from the requirement to consult the prescription monitoring program if the medications are for inpatient use or to provide emergency care, or the prescription monitoring program cannot be accessed

Hearing Date: 1/12/18

Staff: Kim Weidenaar (786-7120).

Background:

The Department of Health (DOH) maintains a prescription monitoring program (PMP) to monitor the prescribing and dispensing of controlled substances and other drugs that demonstrate a potential for abuse. Each time one of these drugs is dispensed, the dispenser must electronically submit the following information to the PMP:

Prescribers are not required to query the PMP prior to prescribing a controlled substance. Data in the PMP may be accessed by:

A dispenser or practitioner acting in good faith is immune from civil, criminal, or administrative liability for requesting, receiving, or using information from the PMP.

Summary of Bill:

Prior to issuing a prescription for an opiate or benzodiazepine, a health care practitioner must review the patient's controlled substance history in the prescription monitoring program (PMP). A practitioner is defined to include physicians, osteopathic physicians, dentists, podiatric physicians, physician assistants and osteopathic physician assistants that are approved to prescribed controlled substances, and advanced registered nurse practitioners licensed to prescribe controlled substances.

In addition to reviewing a patient's controlled substance history in the PMP before issuing a prescription for an opiate or benzodiazepine, a practitioner must document in the patient's chart the review of the PMP. Practitioners are not required to consult the PMP if:

If the practitioner does not review the patient's history in the PMP, the practitioner must document why the review was not performed, including the specific exception.

Appropriation: None.

Fiscal Note: Requested on January 3, 2018.

Effective Date: The bill takes effect 90 days after adjournment of the session in which the bill is passed.